Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Micronized Progesterone Versus Levonorgestrel for Treatment of Non-atypical Endometrial Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal Patients~* Patients with histologically confirmed endometrial hyperplasia without atypia~Exclusion Criteria:~* Endometrial hyperplasia with atypia~* Endometrial Carcinoma~* Suspected pathology on Physical/Ultrasonographic Examination e.g. fibroids, adnexal abnormality

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Vaginal Micronized Progesterone (Type: EXPERIMENTAL): Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months. With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
- LNG-IUS (Type: ACTIVE_COMPARATOR): Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day with one year follow up.

Based on this trial design, predict the completion outcome and termination type (if applicable).